🦴 Hypercalcemia Management
UseSpecific treatment and doses follow current guidelines and local protocols; this page does not list them. [Pe…
SourceEl-Hajj Fuleihan G, et al. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society…
This-shift next steps
After scoring: open the scene pack, peer scores, and the matching pathway. Local reference — no HIS write.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
Methodology · worked example, guidelines & full notes
reserve it for volume overload after rehydration. (original synthesis · not guideline verbatim)
When to use
Specific treatment and doses follow current guidelines and local protocols; this page does not list them. [Pending update] Unsourced specific doses/regimens on this page are temporarily hidden pending item-by-item review against the cited guideline texts.
How it works
Mild asymptomatic Moderate-severe/symptomatic.
Key points
- reserve it for volume overload after rehydration. (original synthesis · not guideline verbatim)
- Denosumab is preferred when renal impairment or a bisphosphonate contraindication is present, and for refractory/recurrent cases.
- Calcitriol-mediated hypercalcemia (vitamin D toxicity, granulomatous disease, lymphoma) responds to glucocorticoids.
References
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Calcium level | Moderate (3.0–3.5 / 12–14) |
|---|---|
| Symptoms | Symptomatic |
| Renal impairment or bisphosphonate contraindication | No |
→DispositionModerate/symptomatic: aggressive calcium-lowering
- First-line fluids：IV normal saline to correct dehydration and promote urinary calcium excretion (target urine output); after adequate fluids, add loop diuretic (furosemide) for those at risk of volume overload (heart failure/renal impairment) — never give a loop diuretic before fluids
- Inhibit bone resorption：IV bisphosphonate: zoledronic acid infused over (superior to pamidronate; onset 2–4 days); switch to denosumab in renal impairment
- Rapid short-term：Calcitonin SC/IM is rapid but short-acting
| Calcium level | Severe (> 3.5 mmol/L / > 14 mg/dL) |
|---|---|
| Symptoms | Asymptomatic |
| Renal impairment or bisphosphonate contraindication | Yes |
→DispositionSpecific treatment and doses follow current guidelines and local protocols; this page does not list them. [Pending update] Unsourced specific doses/regimens on this page are temporarily hidden pending item-by-item review against the cited guideline texts.
- First-line fluids：IV normal saline to correct dehydration and promote urinary calcium excretion (target urine output); after adequate fluids, add loop diuretic (furosemide) for those at risk of volume overload (heart failure/renal impairment) — never give a loop diuretic before fluids
- Inhibit bone resorption：Denosumab (not renally cleared, suitable for renal impairment or bisphosphonate contraindication; also for refractory/recurrent)
- Rapid short-term：Calcitonin SC/IM is rapid but short-acting
Verification & sources · governance
FAQ
Frequently asked questions
- What are the limits and cautions when using Hypercalcemia Management?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- Does Hypercalcemia Management upload patient data? Where is it calculated?
- Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.